It is critically important that more than 70% of patients with positive receptor status (ERα+, PR+) are initially susceptible to tamoxifen therapy; generally, in this group, there is a high percentage of patients demonstrating objective response to the drug during adjuvant and neoadjuvant treatment of breast cancer. Here, ESR1 is linked to breast cancer.